Owlet Inc. Class A (OWLT) Peer Comparison

$5.04

$0.01 (0.20%)

As on 04-Sep-2026 13:44EDT

Market cap

$147 Mln

Revenue (TTM)

$115 Mln

P/E Ratio

--

P/B Ratio

5.7

Div. Yield

0 %

Edit

	Owlet Inc. Class A (OWLT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	147	12,650	10,638	9,762	9,948
Revenue ($ Mln)	115	1,505	613	2,589	785
Net Profit ($ Mln)	-8.99	160.59	-188.05	222.40	41.54
Net Margin (%)	-7.83	10.67	-30.68	8.59	5.29
RoE (%)	-24.20	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.29	--	44.47	251.81
Price-To-Book	5.67	8.31	15.27	1.36	4.86

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Owlet Inc. Class A (OWLT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	114.90	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	52.03	483.98	127.96	1,245.50	384.30
Gross Profit	53.53	942.44	393.22	1,343.60	347.62
Operating Expenses	70.33	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-7.41	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-9.00	203.83	-192.83	350.40	52.15
Provision for Tax	-0.01	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-8.99	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Owlet Inc. Class A (OWLT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	38.90	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	0.90	210.18	135.71	2,116.80	705.49
Current Liabilities	53.80	233.78	102.33	961.30	132.66
Total Liabilities	85.60	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	Owlet Inc. Class A (OWLT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	5.30	630.60	404.74	7,231.50	1,749.63
Current Assets	88.30	1,344.12	515.78	3,020.50	1,200.55
Total Assets	85.60	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	3.60	212.71	102.84	1,203.70	690.94
Net Current Assets	0.00	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	Owlet Inc. Class A (OWLT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-10.80	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-0.94	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	32.10	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Owlet Inc. Class A (OWLT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-202.70	11.76	-22.53	8.98	1.79
ROE (%)	-24.20	10.86	-28.10	3.04	1.97
ROA (%)	-6.03	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-5.46	13.63	-30.58	-5.99	9.87
Net Margin (%)	-7.83	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Owlet Inc. Class A (OWLT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	27.96	17.55	41.55	1.37	16.49
EBIT Growth (%)	86.61	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	81.76	8.72	-102.66	-30.32	400.42
EPS Growth (%)	90.63	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	145.46	17.33	-12.65	2.19	2.16

Valuation Ratios

	Owlet Inc. Class A (OWLT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-10.20	68.93	-34.59	--	189.42
Price / Book Value	5.67	8.31	15.27	--	4.40
Dividend Yield (%)	0.00	0.00	0.00	--	--
EV/EBITDA	-21.98	55.45	-73.80	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Owlet Inc. Class A (OWLT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.00	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.09	0.01	0.00	0.06	0.01
Current Ratio	1.64	5.75	5.04	3.14	9.05
Quick Ratio	1.35	3.86	4.46	2.33	7.64
Interest Coverage	-2.18	157.91	-38.31	8.18	3.36

Operating Efficiency Ratios

	Owlet Inc. Class A (OWLT)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	28.81	12.65	22.67	17.06	20.09
Asset Turnover	0.77	0.74	0.59	0.24	0.26
Receivable days	60.53	46.54	60.95	65.39	72.41
Inventory Days	90.39	331.92	193.84	221.09	146.53
Payable days	81.49	26.16	60.19	37.02	29.05
Cash Conversion Cycle	69.43	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly